Award recognizes exceptional service to the field of radiation oncology and cancer care
NEW YORK, NY, July 20, 2023 — The world’s largest society for radiation oncology professionals recently voted to confer upon Dr. Charles B. Simone II, FACRO, the designation of Fellow of the American Society for Radiation Oncology (FASTRO). Dr. Simone will receive his FASTRO designation at an awards ceremony in San Diego on Tuesday, October 3, during ASTRO’s 65th Annual Meeting.
It is a rare achievement to receive fellow designations from both ASTRO and the American College of Radiation Oncology (ACRO), and Dr. Simone is one of only a select handful of individuals who have been awarded this designation by both of the two largest radiation oncology societies in the United States. He is also one of the youngest in ASTRO’s history to ever receive this prestigious honor.
“Dr. Charles B. Simone II, Chief Medical Officer at New York Proton Center, joins an elite group of just 29 physicians and medical physicists who are recognized this year for their far-reaching contributions to the field of radiation oncology and their progress in advancing cancer research, education and patient care,” said Geraldine M. Jacobson, MD, MBA, MPH, FASTRO, Chair of the ASTRO Board of Directors. “Congratulations to Dr. Simone for achieving the designation of ASTRO Fellow.”
Awarded annually since 2006, the ASTRO Fellows program recognizes individuals who have made significant contributions to radiation oncology through research, education, patient care and/or service to the field. Since its inception, the FASTRO designation has been awarded to just 450 of ASTRO’s 10,000 members worldwide.
About the New York Proton Center
The New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers—Memorial Sloan Kettering Cancer Center, Montefiore Health System, Mount Sinai Health System—the New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy.